Daiwa Securities Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Daiwa Securities Group’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-644	Closed	-$2K	–	1272
2020 Q2	$2K	Hold	644	–	–	﹤0.01%	1177
2020 Q1	$2K	Hold	644	–	–	﹤0.01%	1179
2019 Q4	$2K	Sell	644 -209	-25%	-$607	﹤0.01%	1181
2019 Q3	$2K	Hold	853	–	–	﹤0.01%	1146
2019 Q2	$3K	Hold	853	–	–	﹤0.01%	1141
2019 Q1	$3K	Hold	853	–	–	﹤0.01%	1123
2018 Q4	$2K	Hold	853	–	–	﹤0.01%	1121
2018 Q3	$2K	Hold	853	–	–	﹤0.01%	1142
2018 Q2	$2K	Hold	853	–	–	﹤0.01%	1159
2018 Q1	$3K	Buy	+853	New	+$2.33K	﹤0.01%	1114
2014 Q3	–	Sell	-29,644	Closed	-$283K	–	948
2014 Q2	$283K	Sell	29,644 -175,075	-86%	-$1.56M	﹤0.01%	556
2014 Q1	$1.7M	Buy	+204,719	New	+$1.75M	0.01%	242

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Daiwa Securities Group's PDLI Position: Q3 2020 in Review

Daiwa Securities Group sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 644 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in PDLI in Q1 2014 and held it in 12 quarters. The position peaked at $1.7M in Q1 2014. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

Daiwa Securities Group reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
Daiwa Securities Group sold 644 PDL BioPharma, Inc. shares in Q3 2020, an estimated $2K.
Daiwa Securities Group first reported a position in PDL BioPharma, Inc. in Q1 2014 and held it in 12 quarters.
Daiwa Securities Group's PDL BioPharma, Inc. position peaked at $1.7M in Q1 2014.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on Daiwa Securities Group's 13F filing for Q3 2020, filed 2 Nov 2020.